Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Bazedoxifene shows potential as endometriosis therapy in preclinical study

April 14, 2010

Preliminary data disclosed from long-term safety/efficacy phase III trial of LibiGel in HSDD

April 14, 2010

Karo Bio identifies novel estrogen receptor beta ligands

April 14, 2010

Novartis claims new inhibitors of SGLT-1 and SGLT-2

April 14, 2010

HRA licences additional rights for Esmya to PregLem for benign gynecological disorders

April 13, 2010

Vantia discloses dysmenorrhea candidate VA-111913 at ACS meeting

April 13, 2010

Gaucher's disease patients achieve key therapeutic goals with velaglucerase alfa

April 13, 2010

Johnson & Johnson reports new HIF prolyl hydroxylase inhibitors

April 13, 2010

Promising preclinical data presented on DGAT-1 inhibitor PF-04620110

April 12, 2010

New semicarbazide-sensitive amine oxidase inhibitors disclosed by Hungarian researchers

April 12, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...